Unexpected Anaphylaxis After Completing a Desensitization Protocol to Oxaliplatin: Successful Adjuvant Use of Omalizumab

摘要

Omalizumab is a recombinant humanized anti-IgE monoclonal antibody. It binds to free serum IgE, thus downregulating expression of FcεRI on the surface of mast cells and basophils [1]. It also dissociates prebound IgE from mast cells and basophils, with a reduction in cell-signaling events [2]. Omalizumab is approved for the treatment of severe allergic asthma and chronic urticaria. However, it has been used as off-label therapy in other conditions, such as rhinitis, nasal polyposis, atopic dermatitis, and mastocytosis. It has also been used as an adjuvant to increase tolerance and safety in specific oral tolerance.